Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma

Retina

Volumn 37, Issue 1, 2017, Pages 173-178

  Vié, Anne Laure ^a   Kodjikian, Laurent ^a   Malclès, Ariane ^b   Agard, Emilie ^b   Voirin, Nicolas ^c   El Chehab, Hussam ^b   Nguyen, Anh Minh ^a   Dot, Corinne ^b  

^a CROIX ROUSSE HOSPITAL   (France)

^b HIA Desgenettes   (France)

^c APRET   (France)

Author keywords

DEX implant; Hypotensive treatment; Intraocular pressure; Laucoma; Retina

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DEXAMETHASONE; PROSTAGLANDIN DERIVATIVE; VASCULOTROPIN INHIBITOR; DELAYED RELEASE FORMULATION; DRUG IMPLANT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FILTERING OPERATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CASE CONTROL STUDY; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG IMPLANT; FEMALE; GLAUCOMA, OPEN-ANGLE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY; VISUAL FIELD;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; VISUAL FIELDS;

EID: 84979980444     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001114     Document Type: Article

References (17)

1. Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
2. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethazone intravitreal implant in patients with diabetic macular edema, Ophtalmology 2014;121:1904-1914.
3. Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-553.
4. Bellocq D, Korobelnik J-F, Burillon C, et al. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. Br J Ophthalmol 2015;99:979-983.
5. Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 2013;58:291-310.
6. Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with centre and hemicentral retinal vein occlusion. Ophtalmology 2004;111:133-141.
7. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-507.
8. Reid GA, Sahota DS, Sarhan M. Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 2015;35:1647-1655.
9. François J. Cortisone et tension oculaire [in French]. Ann Ocul (Paris) 1954;187:805-816.
10. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491.
11. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963;70:492-499.
12. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina 2008;28:573-580.
13. Bakri SJ, Omar AF, Lezzi R, Kapoor KG. Evaluation of multiple dexamethasone intravitreal implant patients with macular edema associated with retinal vein occlusion. Retina 2016;36: 552-557.
14. Matonti F, Meyer F, Guigou S, et al. Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 2013;91:e584-e586.
15. Caillaux V, Valtot F, Souied EH, Mimoun G. Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion. Eur J Ophthalmol 2015;25:454-458.
16. Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009;116:455-460.
17. Capone A Jr., Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014;34:342-351.